Altered functions of natural killer cells in response to L-Arginine availability

Cellular Immunology

Volumn 280, Issue 2, 2012, Pages 182-190

  Lamas, Bruno ^a   Vergnaud Gauduchon, Juliette ^a   Goncalves Mendes, Nicolas ^a   Perche, Olivier ^a   Rossary, Adrien ^a   Vasson, Marie Paule ^a,b   Farges, Marie Chantal ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CENTRE JEAN PERRIN   (France)

Author keywords

Activating receptors; Cytotoxicity; IFN production; L Arginine depletion; NK cells

Indexed keywords

ARGININE; GAMMA INTERFERON; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER 92 ACTIVATING RECEPTOR; NATURAL KILLER CELL RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; ARGININE DEFICIENCY; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON PRODUCTION; LYMPHOMA CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ARGININE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3;

EID: 84873517014     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.11.018     Document Type: Article

References (48)

1. Bronte V., Zanovello P. Regulation of immune responses by L-Arginine metabolism. Nat. Rev. Immunol. 2005, 5:641-654.
2. Peranzoni E., Marigo I., Dolcetti L., Ugel S., Sonda N., Taschin E., Mantelli B., Bronte V., Zanovello P. Role of arginine metabolism in immunity and immunopathology. Immunobiology 2007, 212:795-812.
3. Nicholson B., Manner C.K., Kleeman J., MacLeod C.L. Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J. Biol. Chem. 2001, 276:15881-15885.
4. Yeramian A., Martin L., Serrat N., Arpa L., Soler C., Bertran J., McLeod C., Palacin M., Modolell M., Lloberas J., Celada A. Arginine transport via cationic amino acid transporter 2 plays a critical regulatory role in classical or alternative activation of macrophages. J. Immunol. 2006, 176:5918-5924.
5. Hesse M., Modolell M., La Flamme A.C., Schito M., Fuentes J.M., Cheever A.W., Pearce E.J., Wynn T.A. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-Arginine metabolism. J. Immunol. 2001, 167:6533-6544.
6. Munder M., Eichmann K., Moran J.M., Centeno F., Soler G., Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 1999, 163:3771-3777.
7. Munder M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 2009, 158:638-651.
8. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 2008, 222:180-191.
9. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65.
10. Viola A., Bronte V. Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin. Cancer Biol. 2007, 17:309-316.
11. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B., Ochoa A.C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004, 64:5839-5849.
12. Vissers Y.L., Dejong C.H., Luiking Y.C., Fearon K.C., von Meyenfeldt M.F., Deutz N.E. Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency?. Am. J. Clin. Nutr. 2005, 81:1142-1146.
13. Munder M., Schneider H., Luckner C., Giese T., Langhans C.D., Fuentes J.M., Kropf P., Mueller I., Kolb A., Modolell M., Ho A.D. Suppression of T-cell functions by human granulocyte arginase. Blood 2006, 108:1627-1634.
14. Rodriguez P.C., Quiceno D.G., Ochoa A.C. L-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573.
15. Rodriguez P.C., Zea A.H., DeSalvo J., Culotta K.S., Zabaleta J., Quiceno D.G., Ochoa J.B., Ochoa A.C. L-Arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 2003, 171:1232-1239.
16. Zea A.H., Rodriguez P.C., Culotta K.S., Hernandez C.P., DeSalvo J., Ochoa J.B., Park H.J., Zabaleta J., Ochoa A.C. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004, 232:21-31.
17. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 2004, 4:675-687.
18. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
19. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
20. Bloushtain N., Qimron U., Bar-Ilan A., Hershkovitz O., Gazit R., Fima E., Korc M., Vlodavsky I., Bovin N.V., Porgador A. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J. Immunol. 2004, 173:2392-2401.
21. Arnon T.I., Lev M., Katz G., Chernobrov Y., Porgador A., Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. 2001, 31:2680-2689.
22. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., Davis D.M., Strominger J.L., Yewdell J.W., Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
23. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B., Haldeman B., Ostrander C.D., Kaifu T., Chabannon C., Moretta A., West R., Xu W., Vivier E., Levin S.D. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 2009, 206:1495-1503.
24. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 2008, 9:495-502.
25. Vujanovic N.L., Yasumura S., Hirabayashi H., Lin W.C., Watkins S., Herberman R.B., Whiteside T.L. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J. Immunol. 1995, 154:281-289.
26. Caligiuri M.A., Zmuidzinas A., Manley T.J., Levine H., Smith K.A., Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptor. J. Exp. Med. 1990, 171:1509-1526.
27. Choi B.S., Martinez-Falero I.C., Corset C., Munder M., Modolell M., Muller I., Kropf P. Differential impact of L-Arginine deprivation on the activation and effector functions of T cells and macrophages. J. Leukocyte Biol. 2009, 85:268-277.
28. Oberlies J., Watzl C., Giese T., Luckner C., Kropf P., Muller I., Ho A.D., Munder M. Regulation of NK cell function by human granulocyte arginase. J. Immunol. 2009, 182:5259-5267.
29. Xiao L., Eneroth P.H., Qureshi G.A. Nitric oxide synthase pathway may mediate human natural killer cell cytotoxicity. Scand. J. Immunol. 1995, 42:505-511.
30. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8:652-658.
31. Czekanska E.M. Assessment of cell proliferation with resazurin-based fluorescent dye. Methods Mol. Biol. 2011, 740:27-32.
32. Allegra S., Deleine C., Michael-Jubely R., Gryson C., Boirie Y., Kantakamalakul W., Vasson M.P. Implementation of the EGFP-K562 flow cytometric NK test: determination of NK cytotoxic activity in healthy elderly volunteers before and after feeding. Cytometry A 2006, 69:992-998.
33. Merlin E., Goncalves-Mendes N., Hannani D., de la Torre A., Farges M.C., Laroye H., Demeocq F., Kanold J., Vasson M.P. Extracorporeal photochemotherapy induces arginase 1 in patients with graft vs host disease. Trans. Immunol. 2011, 24:100-106.
34. Li H., Han Y., Guo Q., Zhang M., Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009, 182:240-249.
35. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A.C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65:3044-3048.
36. Furuke K., Burd P.R., Horvath-Arcidiacono J.A., Hori K., Mostowski H., Bloom E.T. Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha. J. Immunol. 1999, 163:1473-1480.
37. Jarahian M., Fiedler M., Cohnen A., Djandji D., Hammerling G.J., Gati C., Cerwenka A., Turner P.C., Moyer R.W., Watzl C., Hengel H., Momburg F. Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog 2011, 7:e1002195.
38. Mamessier E., Sylvain A., Bertucci F., Castellano R., Finetti P., Houvenaeghel G., Charaffe-Jaufret E., Birnbaum D., Moretta A., Olive D. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011, 71:6621-6632.
39. Taheri F., Ochoa J.B., Faghiri Z., Culotta K., Park H.J., Lan M.S., Zea A.H., Ochoa A.C. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin. Cancer Res. 2001, 7:958s-965s.
40. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2:907-916.
41. Critchley-Thorne R.J., Simons D.L., Yan N., Miyahira A.K., Dirbas F.M., Johnson D.L., Swetter S.M., Carlson R.W., Fisher G.A., Koong A., Holmes S., Lee P.P. Impaired interferon signaling is a common immune defect in human cancer. Proc. Nat. Acad. Sci. USA 2009, 106:9010-9015.
42. Strowig T., Brilot F., Munz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J. Immunol. 2008, 180:7785-7791.
43. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13:95-109.
44. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97:192-197.
45. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998, 161:2833-2840.
46. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
47. Hatzoglou M., Fernandez J., Yaman I., Closs E. Regulation of cationic amino acid transport: the story of the CAT-1 transporter. Annu. Rev. Nutr. 2004, 24:377-399.
48. Stevens B.R., Tellier M., Harvey W., Feldman D.H., Bosworth J. Interleukin-2 and concanavalin A upregulate a cat2 isoform encoding a high affinity L-Arginine transporter in feline lymphocytes. Can. J. Vet. Res. 2000, 64:187-191.